# Gilead Sciences, Inc. (GILD) — Q1-2017 Earnings Results

**Report date:** 2017-05-02 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2017

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Reaction Not Available

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.23 | N/A | -3.21% |

### Management Commentary

**Tone:** Neutral

Management acknowledged the competitive landscape but expressed commitment to advancing their product pipeline. They highlighted the importance of strategic investments moving forward.

**Key quotes:**

> Management noted ongoing challenges in the market.

> They emphasized a focus on innovation and pipeline development.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

This earnings report indicates that Gilead Sciences faced some challenges in meeting earnings expectations, as reflected in the slight EPS miss. The lack of guidance may leave investors uncertain about the company's future performance. Overall, the market's reaction to this report remains unclear due to missing stock reaction data.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2017_